Latest Developments
03 February 2011
A5 Laboratories has received approval letter for it’s containment level 2 facility.
MONTREAL, QUEBEC–(Marketwire – 02/03/11) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today the office of Biohazard and Containment Safety
01 February 2011
A5 Laboratories, Inc. Announces Successful Production of VI-1718 Interferon Product
MONTREAL, QUEBEC–(Marketwire – 02/01/11) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today the successful production of its VI-1718 interferon product by its European manufacturing partner.
Business
A5 Laboratories Business Process
- Identify novel platform for production of existing interferon products
- Secure IP
- Use internal CRO capability to generate revenue and reduce development cost
- Conduct preliminary pilot studies
- Secure market
We have Expertise in Regulatory Affairs
- DIN – Drug identification Number
- New Drug Submissions (NDS)
- Supplement to a NDS (SNDS)
- Supplemenet to a NDS – Confirmatory (SNDS-C)
- Abbreviated New Drug Submissions (ANDS)
- Prority Reviews
